Last reviewed · How we verify
AL3818 Capsule
AL3818 is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
AL3818 is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | AL3818 Capsule |
|---|---|
| Also known as | Anlotinib hydrochloride, Catequentenib, Anlotinib, Anlotinib Hydrochloride, Catequentinib |
| Sponsor | Advenchen Laboratories Nanjing Ltd. |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | FGFR, VEGFR, and other receptor tyrosine kinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AL3818 inhibits several key kinases including FGFR, VEGFR, and other receptor tyrosine kinases that drive tumor cell proliferation and promote new blood vessel formation. By blocking these pathways, the drug aims to suppress tumor growth and limit the blood supply to cancer cells. This multi-targeted approach is designed to provide anti-tumor and anti-angiogenic activity.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Hypertension
- Anorexia
Key clinical trials
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (PHASE3)
- Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers (PHASE1)
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
- Anlotinib Capsules in the Treatment for IPF/PF-ILDs (PHASE2, PHASE3)
- Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (PHASE2)
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma (PHASE3)
- A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |